Several studies suggest that inhibition or altering TNF‐α may exert therapeutic effect on DKD41, 42 even in humans.43 In our study Φ‐NGAL macrophage cell therapy increased the anti‐inflammatory molecule IL‐10 and decreased the pro‐inflammatory molecule TNF‐α, suggesting that Φ‐NGAL macrophages could reduce inflammation in DKD. This evidence concerns the gene LCN2 and diabetic kidney disease.